证券代码：688363 证券简称：华熙生物 公告编号：2025-044 华熙生物科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 27 日（星期四）至 12 月 03 日（星期三）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@bloomagebiotech.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 华熙生物科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 29 日发 布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 12 月 04 日（星期四） 10:00-11:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次业绩说明会以网络互动形式召开，公司将针对 2025 年第三季度的经营 成果及财务指标的 ...

Core Viewpoint - Social media has become the primary information source for young cosmetic surgery consumers, with a focus on a new injectable material called Calcium Hydroxylapatite (CaHA), which is gaining popularity in the aesthetic market [3][5]. Market Overview - In the global dermal filler market, hyaluronic acid holds a dominant 77% market share, while Calcium Hydroxylapatite accounts for 7% [3]. - Merz Aesthetics' Radiesse is currently the only FDA-approved Calcium Hydroxylapatite facial filler, recently launched in China [5]. Regulatory and Compliance Issues - There are concerns regarding the high prices of these new products, leading to potential exploitation by some cosmetic institutions [6]. - Only two approved products for facial injection in China are Radiesse and Aphranel, while others are approved for non-weight-bearing bone defects [6]. - The use of Calcium Hydroxylapatite in aesthetic applications must adhere to strict regulatory standards, with a clear distinction between products intended for medical and aesthetic use [9]. Consumer Awareness and Safety - Consumers are advised to be cautious and verify the legitimacy of products before use, as many products are not intended for aesthetic applications [8][10]. - Misleading advertising and unverified information on social media pose significant risks to consumers, particularly younger individuals [10]. - The importance of using qualified medical professionals for injections is emphasized, as improper techniques can lead to serious complications [10].

Core Viewpoint - Social media has become the primary information source for young cosmetic consumers, with a growing interest in calcium hydroxyapatite (CaHA) as a regenerative injectable material, often referred to as the "hardest hyaluronic acid" [1] Market Overview - Hyaluronic acid currently holds a dominant 77% market share in the global dermal filler market, while calcium hydroxyapatite accounts for 7% [1] - Merz Aesthetics' Radiesse is the only FDA-approved calcium hydroxyapatite facial filler in the global market, recently approved in China [2] - Domestic companies such as Haohai Biological Technology, Huaxi Biological, and Juzhi Biological are actively developing calcium hydroxyapatite products, intensifying market competition [2] Regulatory and Safety Concerns - Only two calcium hydroxyapatite products are approved for facial injection in China, highlighting the limited scope of approved applications [2] - The use of calcium hydroxyapatite in cosmetic procedures is subject to strict regulatory oversight, requiring clinical trials for injectable products, which can take 6 to 7 years for approval [4] - There are concerns regarding the misuse of calcium hydroxyapatite products, with reports of unqualified products being injected in medical aesthetic clinics [2][4] Consumer Awareness and Risks - The medical aesthetic market faces challenges with misleading advertising and the promotion of unapproved products, leading to potential consumer harm [6] - Experts emphasize the importance of consumers verifying the legitimacy of products and the qualifications of practitioners before undergoing treatments [5][6] - The industry is marked by a disconnect between regulatory bodies, manufacturers, and medical aesthetic institutions, complicating compliance and consumer safety [4]

Core Viewpoint - Recent consumer complaints regarding unqualified products used in medical beauty clinics have sparked discussions about the off-label use of calcium hydroxyapatite (CaHA) aesthetic products [1][2] Industry Overview - Social media has become the primary information source for young consumers in the medical beauty sector, with many influencers promoting CaHA as a regenerative injection material [1] - In the global dermal filler market, hyaluronic acid holds a dominant 77% market share, while CaHA accounts for 7% [1] Product Approval and Market Competition - Merz Aesthetics' Radiesse is currently the only FDA-approved CaHA facial filler, which received approval from China's drug regulatory authority in March and has recently launched in the domestic market [2] - Domestic companies such as Haohai Biological Technology, Huaxi Biological, and Juzhi Biological are actively developing CaHA products, intensifying market competition [2] Regulatory and Safety Concerns - Only two approved CaHA fillers in China are indicated for facial injection, while others are approved for non-load-bearing bone defects [2] - The safety of CaHA as a biomaterial has been established since the 1970s, but its off-label use can lead to complications such as inflammation and nodules [3] Consumer Awareness and Risks - Approximately 200 CaHA products have been approved in China, primarily for orthopedic and dental use, not for aesthetic applications [4] - The regulatory framework requires medical devices and drugs to undergo strict classification and approval processes, but some manufacturers may use misleading marketing strategies [5] Recommendations for Consumers - Consumers are advised to seek treatment from reputable institutions and verify product authenticity before procedures [6] - Medical professionals performing CaHA injections must have the necessary qualifications and training to minimize risks [6] - Misleading advertising and unverified information on social media pose significant risks to consumers, particularly younger individuals [6]

天眼查App显示，近日，华熙生物科学技术研究院（北京）有限公司新增一则简易注销公告，公告期为 11月13日至12月3日。 该公司成立于2021年11月，法定代表人为孙京军，注册资本300万人民币，经营范围包括工程和技术研 究和试验发展、技术进出口、经济贸易咨询、承办展览展示活动等。股东信息显示，该公司由华熙生物 （688363）全资持股。 ...

天眼查App显示，近日，华熙生物科学技术研究院（北京）有限公司新增一则简易注销公告，公告期为 11月13日至12月3日。该公司成立于2021年11月，法定代表人为孙京军，注册资本300万人民币，经营范 围包括工程和技术研究和试验发展、技术进出口、经济贸易咨询、承办展览展示活动等。股东信息显 示，该公司由华熙生物（688363）全资持股。 ...

Core Insights - The overall brand communication effectiveness of Shandong listed companies in October 2025 shows a slight decline in the average Network Communication Influence Index (INC Index) to 578.32, down 0.78% from September [1][3] - The company with the most significant increase in ranking is Dezhou United Petroleum Technology Co., Ltd., which rose by 222 positions, while Gome Communication Equipment Co., Ltd. saw the largest drop, falling by 168 positions [1] - The top ten companies in the INC Index include Dong'e Ejiao Co., Ltd., Qingdao Beer Co., Ltd., and Haier Smart Home Co., Ltd., among others, with Huaxi Biotechnology Co., Ltd. showing the most significant improvement, rising 5 places [1] Industry Overall Analysis - The average INC Index of 578.32 indicates that most brands in the industry are maturing and gaining more attention, with brand voice and social concern on the rise [3] - The skewness coefficient of the INC Index is 0.866, indicating a moderate right-skewed distribution, where a few units perform exceptionally well, enhancing the overall industry INC level [3] Communication Breadth Analysis - The average communication breadth score is 2.67, categorized as "standard level," suggesting that the overall voice of Shandong listed companies is at a moderate level [5] - 11 companies achieved the highest level (5), while 72 companies reached level 4, indicating a strong performance in communication breadth [5] - 34 companies are at level 2, indicating potential for improvement, and 1 company is at the lowest level [5] Communication Heat Analysis - The average communication heat score is 2.33, also at the "standard level," reflecting moderate engagement on media platforms [6] - 7 companies reached the highest level (5), while 44 companies achieved level 4, indicating strong activity and engagement [7] - 101 companies are at level 2, and 3 companies are at the lowest level, suggesting a need for improved content planning [7] Network Attention Analysis - The average network attention score is 1.52, categorized as "regional attention," indicating that most companies have some recognition within local areas [8] - 80 companies achieved level 3 or above, while 114 companies are at level 2, showing varying degrees of brand awareness [9] - 116 companies are at the lowest level, indicating low search frequency for brand keywords [9] Official Website Presentation Analysis - The average official website presentation score is 1.05, below the "standard level," indicating low frequency and quality of information published on company websites [10] - 2 companies achieved the highest level (5), while 3 companies reached level 4, showing some companies excel in their online presence [11] - 174 companies are at the lowest level, highlighting a significant area for improvement in website quality and content [11]

Market Performance - The US hotel sector increased by 2.8%, with Marriott and Hilton rising by 3.8% and 1.83% respectively, demonstrating resilience under pressure[6] - The overseas sportswear sector decreased by 0.2%, with Amer Sports surging by 12.2% due to strong Q3 performance, leading to a revenue increase of 30%[14] - The jewelry sector fell by 2.1%, influenced by AI bubble concerns and reduced expectations for a December rate cut, strengthening the dollar[14] Sector Analysis - The domestic sportswear sector dropped by 2.4%, with major OEMs like Shenzhou International and Crystal International declining by 6.7% and 2.6% respectively due to geopolitical tensions[14] - The retail sector saw a decline of 4.0%, with China Duty Free falling by 10.5% as investors took profits amid uncertain policy outlooks[14] - The pet sector decreased by 5.7%, with concerns over sustainability as sales expenses outpaced revenue growth[14] Valuation Insights - The expected PE for the overseas sportswear sector in 2025 is 29.0x, which is 54% of the past 5-year average[15] - The expected PE for the domestic cosmetics sector is 27.6x, representing 52% of the past 5-year average[15] - Most sectors are valued below their historical 5-year averages, indicating potential investment opportunities[15]

从资金流向上来看，当日医疗美容板块主力资金净流出5875.57万元，游资资金净流入1690.61万元，散户 资金净流入4184.96万元。医疗美容板块个股资金流向见下表： 证券之星消息，11月24日医疗美容板块较上一交易日上涨0.27%，*ST美谷领涨。当日上证指数报收于 3836.77，上涨0.05%。深证成指报收于12585.08，上涨0.37%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 4.07 | 4.63% | 28.52万 | | 1.15亿 | | 688363 | 华熙生物 | 49.78 | 1.86% | 1.87万 | | 9268.75万 | | 300896 | 爱美客 | 66'56 | -1.36% | 2.41万 | | 3.52亿 | | 920982 | 锦波生物 | 216.59 | -1.55% | 7336.92 | | 1.60亿 | | 代码 | 名称 | 主力净流 ...

Core Viewpoint - Huaxi Biological's stock price has shown a decline this year, with a recent increase of 2.03% on November 24, 2023, but overall performance remains weak with significant drops over various time frames [1]. Company Overview - Huaxi Biological Technology Co., Ltd. was established on January 3, 2000, and went public on November 6, 2019. The company is located in Jinan, Shandong Province, and specializes in microbial fermentation and cross-linking technology platforms, developing bioactive materials for health [1]. - The company's business model encompasses a full industry chain from raw materials to medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetic, food manufacturing companies, medical institutions, and end-users [1]. Financial Performance - For the period from January to September 2025, Huaxi Biological reported a revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit attributable to shareholders of 252 million yuan, down 30.29% year-on-year [2]. - Cumulatively, the company has distributed 1.138 billion yuan in dividends since its A-share listing, with 528 million yuan distributed over the past three years [3]. Shareholder Information - As of October 31, 2025, the number of shareholders for Huaxi Biological reached 30,600, an increase of 0.86% from the previous period, while the average circulating shares per person decreased by 0.85% to 15,749 shares [2]. - The top ten circulating shareholders have seen reductions in their holdings, with significant decreases noted for major ETFs such as E Fund's and Huaxia's [3].